<p>Across all human cancers analyzed (A), or specifically in the mantle cell lymphoma cohort (B), in the primary endometrial endometrioid adenocarcinoma TCGA cohort (C), and in the advanced or metastatic endometrial carcinoma MSK-IMPACT cohort (D).</p
CCND1 encodes for the cyclin D1 protein involved in G1/S cell cycle transition. In breast cancer the...
<p>The spectrum and frequencies of mutations identified using MALDI-TOF in 546 gynaecological carcin...
<p>Primary nodes depict GO term pathways enriched for deletions in <i>TP53</i> mutant, high copy num...
<p><i>CCND1</i> mutations in advanced or metastatic endometrial carcinomas of the MSK-IMPACT cohort ...
<p>C-terminal <i>CCND1</i> mutations across other non-endometrial carcinoma and non-mantle cell lymp...
Cyclin D1 (CCND1) is a core cell cycle regulator and is frequently overexpressed in human cancers, o...
<div><p>Cyclin D1 (<i>CCND1</i>) is a core cell cycle regulator and is frequently overexpressed in h...
Women diagnosed with early-stage (FIGO 1) endometrial cancer, grade 1 and 2 can have a good prognosi...
A) Mean clonal and subclonal mutations found in each tumor type. For each tumor type we report: mean...
BackgroundMassive chromosomal aberrations are a signature of advanced cancer, although the factors p...
<p>Individual tumors (T) are indicated by vertical gray bars. Tumors consist of NEECs (T3, T51, T62,...
Synchronous primary endometrial and ovarian cancers (SEOs) represent 10% of all endometrial and ovar...
Massive chromosomal aberrations are a signature of advanced cancer, although the factors promoting t...
A. Percent co-occurring mutations between the four genes using data from Table 1. Total percentage (...
Background: Endometrial cancer is the most common gynecologic malignancy, and the number of new case...
CCND1 encodes for the cyclin D1 protein involved in G1/S cell cycle transition. In breast cancer the...
<p>The spectrum and frequencies of mutations identified using MALDI-TOF in 546 gynaecological carcin...
<p>Primary nodes depict GO term pathways enriched for deletions in <i>TP53</i> mutant, high copy num...
<p><i>CCND1</i> mutations in advanced or metastatic endometrial carcinomas of the MSK-IMPACT cohort ...
<p>C-terminal <i>CCND1</i> mutations across other non-endometrial carcinoma and non-mantle cell lymp...
Cyclin D1 (CCND1) is a core cell cycle regulator and is frequently overexpressed in human cancers, o...
<div><p>Cyclin D1 (<i>CCND1</i>) is a core cell cycle regulator and is frequently overexpressed in h...
Women diagnosed with early-stage (FIGO 1) endometrial cancer, grade 1 and 2 can have a good prognosi...
A) Mean clonal and subclonal mutations found in each tumor type. For each tumor type we report: mean...
BackgroundMassive chromosomal aberrations are a signature of advanced cancer, although the factors p...
<p>Individual tumors (T) are indicated by vertical gray bars. Tumors consist of NEECs (T3, T51, T62,...
Synchronous primary endometrial and ovarian cancers (SEOs) represent 10% of all endometrial and ovar...
Massive chromosomal aberrations are a signature of advanced cancer, although the factors promoting t...
A. Percent co-occurring mutations between the four genes using data from Table 1. Total percentage (...
Background: Endometrial cancer is the most common gynecologic malignancy, and the number of new case...
CCND1 encodes for the cyclin D1 protein involved in G1/S cell cycle transition. In breast cancer the...
<p>The spectrum and frequencies of mutations identified using MALDI-TOF in 546 gynaecological carcin...
<p>Primary nodes depict GO term pathways enriched for deletions in <i>TP53</i> mutant, high copy num...
DOI
Add to ORKG